{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"7.19","value":"7.91"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Gemcitabine: Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.13","value":"2.66"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"Gemcitabine: Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.59","value":"3.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"Gemcitabine: Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.91","value":"9.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"}],"units":"Participants"}],"title":"Gemcitabine: Week 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.43","value":"3.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Gemcitabine: Week 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.58","value":"0.744"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"Gemcitabine: Week 21"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.40","value":"1.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"title":"dFdU: Week 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.4","value":"6.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"dFdU: Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.45","value":"6.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"}],"units":"Participants"}],"title":"dFdU: Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.48","value":"5.06"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"title":"dFdU: Week 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.67","value":"2.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"title":"dFdU: Week 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.23","value":"6.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"title":"dFdU: Week 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Urine concentrations of gemcitabine and dFdU were reported.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with papillary disease only, received TAR-200 intravesically Q3W from Week 0 for the first 24 weeks, followed by Q12W dosing through Week 99. TAR-200 was inserted intravesically via UPC.","id":"OG000","title":"Cohort 4: TAR-200 Monotherapy (Papillary Disease Only)"}],"paramType":"MEAN","populationDescription":"FAS included all enrolled participants who received at least 1 dose of study treatment. Here \"N\" (overall number of participants analyzed) signifies number of participants evaluable for this outcome measure, \"n\" (number analyzed) signifies number of participants evaluable at specific timepoints. This OM was planned to be analyzed for Cohort 4 only.","reportingStatus":"POSTED","timeFrame":"At Weeks 3, 6, 9, 15, 18, and 21","title":"Cohort 4: Urine Concentration of Gemcitabine and dFdU (Metabolite)","type":"SECONDARY","unitOfMeasure":"mcg/mL"}